About Mianus Capital
Mianus Capital is a specialist life-sciences investment firm focused on Seed and Pre-A opportunities in early-stage innovation globally. Our platform is differentiated by a strategic partnership with MERIT CRO, Inc., an "insider" in the drug development ecosystem with deep scientific and clinical expertise across our covered therapeutic areas.
We apply a deep understanding of pre-clinical and clinical research to identify high-conviction opportunities early and provide technical endorsement that helps startup companies build credibility with partners and future investors. We construct an ETF-style, diversified portfolio of biotech companies across therapeutic areas, balancing risk while maintaining exposure to breakthrough science.
Mianus Accelerator
We recently launched Mianus Accelerator with MERIT CRO, a strategic initiative designed to deliver a one-stop Capital + Service solution for global biotech companies. Through Mianus Accelerator, we combine capital with deep preclinical and clinical development expertise and cross-border operational resources, enabling innovators to efficiently leverage the global clinical ecosystem - especially China's patient access, clinical execution capabilities, and cost advantages - to accelerate development timelines, generate high-quality data, and drive value creation.
Investment Strategy
Be a trusted capital and operational partner to early-stage biotech entrepreneurs.
Insider & Insight
Strategic partner MERIT CRO, an "insider" in drug development ecosystem, provides insights for investing
Specialist Investor
Deep understanding in pre-clinical and clinical research in each of covered therapeutic areas
Early-Stage Focus
Focus on early-stage, invest in Seed and Pre-A rounds, provide technical endorsement
Execution Support
Leverage pre-clinical and clinical resource of MERIT CRO to accelerate clinical development of portfolio company
Diversification
Build an ETF-style diversified portfolio of biotech companies across therapeutic areas
Mianus Accelerator 
Leverage "China Speed" to Accelerate Clinical Research for Global Biotech Innovation
China's large patient population and supportive regulatory environment have enabled Chinese biotechs to advance early-stage clinical research in a cost-efficient and timely manner. This dynamic has contributed to a significant rise in global out-licensing transactions from Chinese biotech to multinational pharma.
Mianus Accelerator is a strategic initiative launched by Mianus Capital, a U.S.-based early-stage investment platform backed by MERIT CRO, a premier global clinical endpoint service provider. The team believes that combining Western biotech innovation with China's efficient early-stage clinical ecosystem can create substantial value and accelerate the development of transformative therapies for patients worldwide.
Mianus Accelerator offers a one-stop solution to help U.S. and European biotech companies leverage "China Speed" to obtain first-in-human data and advance clinical programs more cost effectively.
Strategic Partner 
MERIT is an innovative, global clinical and preclinical trial endpoint and technology services provider working in a variety of therapeutic areas, including ophthalmology, respiratory, oncology, and cardiology. We partner with pharmaceutical and biotech sponsors as well as CROs to deliver reliable endpoint services in multi-regional trials.
Highlights
- Founded in 2012; headquartered in Wisconsin, USA.
- Ranked among the Top 3 global clinical endpoint CROs.
- Expertise in oncology and respiratory, with a global leadership position in ophthalmology.
- Global operating footprint with 5 offices across the U.S., Canada, and China, with 200+ employees globally.
- Global customers including 13 of the world’s top 20 pharma companies and hundreds of U.S./Europe-based biotech companies.
- Included for 7 consecutive years on America’s Fastest-Growing Private Companies Top 2000 List.
Experts
Scientific Advisory Board
Mianus leverages the SAB of MERIT, which is a team of Scientific Advisors who provide guidance and expertise on strategic direction and industry market trends to inform and advance our research.
Ophthalmology Scientific Advisory Council (SAC)
The Ophthalmology Scientific Advisory Council (SAC) advises both Mianus and MERIT on cutting edge technology and treatments to keep our firm aligned with market needs and assist with fulfilling our mission of driving innovation in life sciences.
Leadership of Mianus Accelerator
Our leadership team brings extensive expertise and hands-on experience across business development, clinical research, fundraising, and entrepreneurship.
Steve Yang
CFA, MBA
Yijun Huang
Ph.D.
David Bingaman
DVM, Ph.D., D.ACVO
Leon Tang
Ph.D.
Grace Gui
News
Stay updated with the latest news and announcements from Mianus Capital and our portfolio companies.
-
January 1, 2026Mianus Capital and MERIT CRO jointly lanuched Mianus Accelerator
-
January 1, 2025Reflecting on 2024: Progress, Challenges, and Opportunities
-
October 25, 2023MERIT and Mianus Capital Announce Formation of Ophthalmology Scientific Advisory Council
Contact
Get in touch with Mianus Capital to discuss investment opportunities, partnerships, or other inquiries.
Address:
U.S. Office
260 Madison Avenue, 8th FL
New York, NY 10016
China Office
上海徐汇区枫林路420号A栋3楼306号
Email: